Phaseline

Companies › Hangzhou Hanx Biopharmaceuticals

Hangzhou Hanx Biopharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HX301–Phase 1GliomaDec 2026
HX009–Phase 1Biliary Tract CancerDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06703255HX301Phase 1GliomaOncologyDec 2026
NCT06708663HX009Phase 1Biliary Tract CancerOncologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.